Singapore markets close in 1 hour 52 minutes

Bio-Rad Laboratories, Inc. (BUWA.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
264.10-0.20 (-0.08%)
As of 08:20AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 7.58B
Enterprise value 7.35B
Trailing P/E N/A
Forward P/E 26.45
PEG ratio (5-yr expected) 1.08
Price/sales (ttm)3.19
Price/book (mrq)0.91
Enterprise value/revenue 3.07
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.94
52-week change 3-24.12%
S&P500 52-week change 324.69%
52-week high 3383.80
52-week low 3248.50
50-day moving average 3275.95
200-day moving average 3296.22

Share statistics

Avg vol (3-month) 32
Avg vol (10-day) 3N/A
Shares outstanding 523.45M
Implied shares outstanding 628.75M
Float 819.97M
% held by insiders 115.23%
% held by institutions 179.85%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -12.37%
Operating margin (ttm)8.48%

Management effectiveness

Return on assets (ttm)1.69%
Return on equity (ttm)-3.43%

Income statement

Revenue (ttm)2.61B
Revenue per share (ttm)90.02
Quarterly revenue growth (yoy)-9.80%
Gross profit (ttm)N/A
EBITDA 502.99M
Net income avi to common (ttm)-322.37M
Diluted EPS (ttm)-9.81
Quarterly earnings growth (yoy)456.70%

Balance sheet

Total cash (mrq)1.65B
Total cash per share (mrq)57.69
Total debt (mrq)1.4B
Total debt/equity (mrq)15.47%
Current ratio (mrq)6.57
Book value per share (mrq)317.32

Cash flow statement

Operating cash flow (ttm)346.57M
Levered free cash flow (ttm)120.82M